Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Hans C LeeKarthik RamasamyMargaret MacroFaith E DaviesRafat AbonourFrits van RheeVania T M HungriaNoemi PuigKaili RenJiri SilarVictoria EnwemaduDasha CherepanovXavier LeleuPublished in: European journal of haematology (2024)
IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide- and/or PI-nonrefractory versus refractory patients.
Keyphrases
- multiple myeloma
- newly diagnosed
- end stage renal disease
- clinical practice
- ejection fraction
- chronic kidney disease
- stem cell transplantation
- systematic review
- acute lymphoblastic leukemia
- acute myeloid leukemia
- metabolic syndrome
- high dose
- adipose tissue
- diffuse large b cell lymphoma
- chronic lymphocytic leukemia